In the NAFLD mice, this was shown to be the result of inefficient progression through the S/G2 phase by activation of the G2/M DNA damage checkpoint, preventing the activation of the cyclinB1/CDK1 complex. This evidence concerns the gene CDK1 and metabolic dysfunction-associated steatotic liver disease.